IL33 and neoplasm: In the realm of immune checkpoint blockade, preclinical work in pancreatic cancer models have shown that combining recombinant IL-33 with PD-1 checkpoint inhibition significantly enhances ILC2-mediated tumor control and prolongs survival, underscoring how checkpoint blockade can reinforce ILC activity within immunosuppressive microenvironments (175).